Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
== "Insulin" == "In 1920 the diagnosis of diabetes, particularly in the young and the very young, was essentially a death sentence." "The discovery of insulin represents a real breakthrough that has revolutionized both the therapy and the prognosis of people with diabetes ... Before insulin, diabetes was a dreadful condition associated with bad prognosis and miserable quality of life ... [progressing to] the ineluctable coma-death sequence. In 1889, Joseph von Mering and Oskar Minkowski reported that, in every case, the complete removal of an experimental dog's pancreas produced severe and fatal diabetes. They hypothesized that the consequent diabetic state was "due to loss of an 'internal secretion' of the pancreas rather than [to a loss] of the pancreatic exocrine secretion" (GL.2, p.2). Over the ensuing years, as the endocrine functions of the pancreas (glucagon, insulin, etc.), rather than its exocrine functions (pancreatic juice, etc.), were becoming increasingly better understood, "many investigators [had] endeavoured to obtain some beneficial effect in diabetes mellitus: either by feeding pancreas, or by administration of pancreatic extracts" (FB.2, p.141). The complete chemical structure of insulin was eventually determined by Frederick Sanger and Edward Thompson in 1953 (FS.2; FS.3): and, in 1965 (YW.1; YS.1), the team led by Wang Yinglai (王应睐/王應睞) was not only the first to create synthetic insulin, but was also, in the process, the first to produce a biologically active organic compound from inorganic chemicals.
=== Muscle tone === Individuals with decreased muscle tone, increased soft tissue around the airway, and structural features that narrow the airway are at high risk for OSA. Men, whose anatomy is typified by increased mass in the torso and neck, are at increased risk of developing sleep apnea, especially in middle age and later. Typically, women experience this condition less frequently and to a lesser degree than do men, owing partially to physiology, but possibly also to differential levels of progesterone. Prevalence in post-menopausal women approaches that of men in the same age range. Women are at greater risk for developing OSA during pregnancy.
Bruker develops and delivers a wide variety of professional and scientific analysis devices including mass spectrometers, single-Crystal and powder X-ray diffractometers, X-ray tomography devices, NMR spectroscopy devices, fluorescence microscopes, raman spectroscopes, atomic-force microscopes, and profilometers.
In May 2024, Cerebras in collaboration with researchers from Sandia National Laboratories, Lawrence Livermore National Laboratory, Los Alamos National Laboratory, and the National Nuclear Security Administration, simulated 800,000 atoms interacting with each other, calculating the interactions in increments of one femtosecond at a time. Each step took just microseconds to compute on the Cerebras WSE-2, much faster than on the Frontier supercomputer. Cerebras was named to the "100 Most Influential Companies list" by Time in May 2024. In June 2024, Cerebras announced a collaboration with Dell Technologies, for AI compute infrastructure for generative AI. In August 2024, Cerebras launched its AI inference service, which it claimed to be ten to twenty times faster than systems built using Nvidia's H100 Hopper graphics processing units. In January 2025, the Mayo Clinic announced a collaboration with Cerebras to combine genomic data with de-identified data from patient records and medical evidence to explore the ability to predict a patient's response to treatments to manage disease. In January 2025, Cerebras announced support for DeepSeek's R1 70B reasoning model at 1,600 tokens/second. In February 2025, Mistral AI began using Cerebras products to power its Le Chat service and reached a speed record. Also in February 2025, Cerebras announced a partnership with Perplexity AI's Sonar model, which runs on Cerebras chips at 1,200 tokens per second.
=== Performance === Early onset of fatigue Decreased aerobic capacity (VO2 max) Poor physical performance Inability to complete workouts Delayed recovery Overtraining can affect the athlete's athletic ability and other areas of life, such as performance in studies or the workforce. An overtrained athlete who is suffering from physical and/or psychological distress could also have trouble socializing with friends and family, studying for an exam, or preparing for work.
Sources: en.wikipedia.org
5 and Savings) Order 1993 (S.I. 1993/1186) Friendly Societies Act 1992 (Consequential Provisions) (No. 2) Regulations 1993 (S.I. 1993/1187) Serbia and Montenegro (United Nations Sanctions) Order 1993 (S.I. 1993/1188) Export of Goods (Control) (Croatian and Bosnian Territories) Order 1993 (S.I. 1993/1189) Education (Schools) Act 1992 (Commencement No. 2 and Transitional Provision) Order 1993 (S.I. 1993/1190) Lothian Region (Electoral Arrangements) Order 1993 (S.I. 1993/1191) Injuries in War (Shore Employments) Compensation (Amendment) Scheme 1993 (S.I. 1993/1192) Electricity (Standards of Performance) Regulations 1993 (S.I. 1993/1193) Diseases of Animals (Approved Disinfectants) (Amendment) Order 1993 (S.I. 1993/1194) Serbia and Montenegro (United Nations Sanctions) (Dependent Territories) Order 1993 (S.I. 1993/1195) Sea Fish Licensing (Time at Sea) (Principles) Order 1993 (S.I. 1993/1196) Third Country Fishing (Enforcement) Order 1993 (S.I. 1993/1197) Police (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1198) Lincolnshire County Council (Tattershall Bridge Reconstruction) Scheme 1991 Confirmation Instrument 1993 (S.I. 1993/1199)
=== Similar species === In Europe, the spring-fruiting Amanita verna is a similar all-white species, as is the autumn-fruiting, white form of Amanita phalloides (deathcap). Both are equally poisonous. In their immature, button-mushroom stage, all these poisonous species could be mistaken for young, white-capped, edible mushrooms (Agaricus species), highlighting the danger of picking immature fruit bodies for food. In general, there are about 22 species that are considered destroying angels.
== Regulation of mRNA stability == Pin1, a parvulin, regulates mRNA stability and expression in certain eukaryotics mRNAs. These mRNAs are GM-CSF, Pth, and TGFβ and each of them have AREs, or AU-rich cis-elements. The ARE binding protein KSRP has a Pin1 binding site. Pin1 binds to this site and dephosphorylates the serine and isomerizes the peptide bond between Ser181 and Pro182. This isomerization causes the decay of Pth mRNA. KSRP, and other ARE binding proteins like AUF1, are thought to affect the other mRNAs through mechanisms similar to Pth, with the requirement of a phosphorylated serine bonded to a proline in a specific conformation. Pin1 also triggers proline isomerization of Stem-Loop Binding Protein (SLBP), allowing it to control the dissociation of SLBP from histone mRNA. This leads to Pin1 being able to affect histone mRNA decay. Pin1 affects many other genes in the form of gene silencing through the disruption of cell pathways, making it important in mRNA turnover by modulating RNA binding protein activity.
In his introduction, he praised Chomsky as "a very vocal and important voice in the wilderness of intellectual life in America" and said that he was "delighted to welcome a person who I think we're all very proud of". Sanders hosted and produced a public-access television program, Bernie Speaks with the Community, from 1986 to 1988. He collaborated with 30 Vermont musicians to record a folk album, We Shall Overcome, in 1987. That same year, US News & World Report ranked Sanders one of America's best mayors. As of 2013, Burlington was regarded as one of the most livable cities in the United States. During a trip to the Soviet Union in 1988, Sanders interviewed the mayor of Burlington's sister city Yaroslavl about housing and health care issues in the two cities. When Sanders left office in 1989, Bouricius, a member of the Burlington city council, said that Sanders had "changed the entire nature of politics in Burlington and also in the state of Vermont".
Sources: en.wikipedia.org
== Licensing and regulation == In the European Union, in the scope of medical devices, the European Court places them in some relation to a specific medical purpose: treating a disease or illness. The Court held that regulating devices that do not explicitly manifest medical benefits as medical devices would run counter to the rationale and lead to overregulation. "The legal foundation for regulating medical devices in the EU is the MDR (Regulation (EU) 2017/745), which was adopted in 2016 and came into effect in 2021. The MDR stipulates that for non-medical devices, the 'requirement to demonstrate a clinical benefit (…) shall be understood as a requirement to demonstrate the performance of the device' (Article 61 para 9 MDR). In other words, devices must demonstrate that they function in the way claimed by manufacturers, instead of showing a therapeutic benefit. Moreover, with respect to the safety of non-medical Annex XVI devices, the MDR lays down the following: For the devices referred to in Annex XVI, the general safety requirements (…) shall be understood to mean that the device, when used under the conditions and for the purposes intended, does not present a risk at all or presents a risk that is no more than the maximum acceptable risk related to the product's use which is consistent with a high level of protection for the safety and health of persons(MDR, Annex I, Article 9). The MDR sets an absolute risk threshold for the non-medical devices listed in Annex XVI, including non-invasive brain stimulation.
=== Doping in sport === Phenylpiracetam has stimulant effects and may be used as a doping agent in sport. As a result, it is on the list of stimulants banned for in-competition use by the World Anti-Doping Agency (WADA). This list is applicable in all Olympic sports. Owing to its unique stimulant properties among racetams, phenylpiracetam is the only racetam on the WADA prohibited list.
In 1948, the Australian psychiatrist John Cade discovered the usefulness of lithium salts in treating mania while working at the Bundoora Repatriation Mental Hospital in Melbourne. He was injecting guinea pigs with urine extracts taken from manic patients in an attempt to isolate a metabolic compound which might be causing mental symptoms. Since uric acid in gout was known to be psychoactive, he needed soluble urate for a control. He used lithium urate, already known to be the most soluble urate compound, and observed that it caused the guinea pigs to become tranquil. Cade traced the effect to the lithium ion itself, and after Cade ingested lithium himself to ensure its safety in humans, he proposed lithium salts as tranquilizers. In 1949, he published his findings in the Medical Journal of Australia in a paper entitled "Lithium salts in the treatment of psychotic excitement". He soon succeeded in controlling mania in chronically hospitalized patients with lithium. This was one of the first successful applications of a drug to treat mental illness, and it opened the door for the development of medicines for other mental problems in the next decades. In 1950, one of Cade's first patients died of lithium toxicity after Cade had successfully treated him and released him from the hospital. Afterward, Cade abandoned the research of lithium and focused instead on testing other salts of rubidium, cerium, and strontium for their potential utility in psychiatry.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
多肽在反相柱上按疏水性差异分离，能有效区分主峰、缺失序列片段与氧化产物。配合紫外检测可获得可量化的纯度百分比，是肽类分析的常规手段。